Glenmark Pharmaceuticals has been granted final approval by the US Food & Drug Administration for Potassium Chloride Extended-Release Capsules USP, 10 mEq, generic version of Actavis Laboratories’ equivalent drug.
Glenmark noted in its press release on Thursday that, according to IMS Health sales data for the 12 motnh period ending November 2015, the Potassium Chloride Extended-Release Capsules, 10 mEq Market achieved annual sales of about $74.1 million.
Glenmark’s current portfolio consists of 105 products authorized for distribution in the U.S. marketplace and 63 ANDA’s pending approval with the FDA.
Generics of Warner Chilcott’s Loestrin
In addition, the company has been granted by the FDA the approval for Nerothindrone Acetate and Ethynyl Estradiol Tablets USP. Those are generic version of Warner Chilcotts Company’s Loestrin tablets.
Sales last year reached about $57 million, according to IMS Health sales data for 2015.